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Ovarian cancer represents the fifth most significant cause of
cancer-related death for women and the most frequent cause
of death from gynaecological neoplasia in the Western world.
The incidence of ovarian cancer in the UK is over 5000 new
cases every year, accounting for 4275 deaths per year (Chang
et al., 1994). A recent meta-analysis of all randomised trials
of patients with epithelial ovarian cancer after surgery dem-
onstrated an overall 5 year survival of 30% (Advanced
Ovarian Cancer Trialists Group, 1991). Five year survival
rates are as follows: stage I, 70%; stage II, 45%; stage III,
17%; and stage IV, 5% (Chang et al., 1994). The high overall
mortality is due to the majority of patients presenting with
stage III and IV disease. Clearly, any methods that enable
the early detection of ovarian cancer would lead to a
significant decrease in mortality.
Ovarian cancer encompasses a broad spectrum of lesions,
ranging from localised benign tumours and tumours of
borderline malignant potential, through to invasive malig-
nant adenocarcinomas. Histologically, the common epithelial
ovarian cancers, which account for 90% of all ovarian
cancer, are classified into several types, that is serous,
mucinous, endometrioid, clear cell, Brenner, mixed epithelial
and undifferentiated tumours. The different histological sub-
types reflect the considerable differentiation potential of the
ovarian surface epithelium.
The aetiology of ovarian cancer is not completely under-
stood, although both epidemiological and genetic associa-
tions have been recorded. Epidemiological factors related to
ovulation seem to be important (Fathalla, 1971), whereby
ovarian epithelial cells undergo several rounds of division
and proliferative growth to heal the wound in the epithelial
surface, thereby increasing the chance of a genetic accident
during the repair process, such as the activation of an
oncogene or the inactivation of a tumour-suppressor gene
(Berek et al., 1993). The genetic changes occurring in
epithelial ovarian cancer are also poorly understood and,
except for the analysis of the p53 gene, the majority have not
yet been defined. This review focuses on the current unders-
tanding of cytogenetic abnormalities, linkage and allele loss
studies that signpost chromosomal regions which may con-
tain relevant genes. The emphasis of this review is on reces-
sively acting rather than dominant genes (reviewed recently
in Berchuck et al., 1992) as the isolation of tumour-
suppressor genes will lay the foundation for an improved
understanding of the mechanisms involved in
tumorigenesis.
Clonality
At surgery, tumours are frequently found in both ovaries and
at other locations in the abdomen and pelvis, raising the
possibility of a multifocal origin. However, it appears that,
like most other neoplasms, ovarian cancer is clonal in origin
(Bello and Rey, 1990; Boltz et al., 1990; Pejovic et al., 1991;
Jacobs et al., 1992; Mok et al., 1992; Tsao et al., 1993).
Correspondence: AN Shelling
Received 8 December 1994; revised 15 March 1995; accepted 22
March 1995
Evidence for clonality is provided when the loss of genetic
material, abnormalities of karyotype and/or point mutations
which have contributed to the initial malignant transforma-
tion are still present in the malignant cells of metastatic
deposits. Several studies (for example Tsao et al., 1993) have
shown that patterns of allelic deletion and chromosome
methylation were identical in both the primary lesion and
associated metastatic tumour within a given patient, thus
providing support for the unifocal origin of ovarian
tumours.
The genetic model for multistep tumour progression of
colorectal tumours (Fearon and Vogelstein, 1990) has
features which may be relevant for ovarian cancer, though
the progression from benign to malignant in ovarian tumours
is controversial (for example Powell et al., 1992). There is
currently no definite evidence to show whether ovarian car-
cinomas develop by multistep progression or whether they
arise de novo, that is each disease stage represents a distinct
entity. At the recent Helene Harris Memorial Trust Meeting
(Blackett and Sharp, 1994) it was concluded that at least a
small proportion of ovarian cancers appear to arise from
pre-existent benign tumours. The uncertainty of the origins
of ovarian cancer may be resolved by the detailed molecular
analysis of tumours.
Tumour-suppressor genes
Recent evidence indicates that a normal cell is converted to a
malignant counterpart following the accumulation of a
critical number of mutations within regulatory genes. These
genes fall into two classes: oncogenes (or proto-oncogenes),
which promote cell growth, and tumour-suppressor genes,
which inhibit cell growth. Proto-oncogenes are necessary for
normal growth and differentiation, but when altered by such
events as mutation, translocation or amplification they func-
tion as transforming oncogenes. The activation of several
proto-oncogenes (such as c-erbB-2, c-fms, c-myc and Ki-ras)
occurs relatively frequently but appears to be unrelated to
prognosis.
Tumour-suppressor genes, like oncogenes,-are involved in
the regulation of cellular growth and differentiation. How-
ever, tumour-suppressor genes act recessively, that is it is the
loss or inactivation of both copies of a tumour-suppressor
gene that removes normal constraints to cell proliferation. In
this model of carcinogenesis, loss or inactivation of a
tumour-suppressor gene can be due to one of several
mechanisms, such as point mutation, deletions, mitotic
recombination and/or chromosomal loss. Many
chromosomal regions have been implicated to contain
tumour-suppressor genes and are thought to be involved in
ovarian tumour progression when analysed by a variety of
approaches.
Cytogenetic abnormalities
In most solid tumours, cytogenetic abnormalities are complex
and it is difficult to identify specific karyotypic changes whichGenetic anlysis of woaan cancer
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are consistently present for a particular type of cancer. The
majority of epithelial ovarian cancers appear to be aneuploid
and contain a vaanetv of structural chromosomal abnor-
malities. However. some non-random chromosomal altera-
tions have been identified in ovarian cell lines and tumours.
including chromosomes 1.3.6.9.11.12.17.19 and X (Wake et
al.. 1980: Whang-Peng et al.. 1984: Atkin and Baker. 1987:
Jenkyn and McCartney. 1987: Sheer et al.. 1987: Smith et al..
1987. 1989; Pejovic et al.. 1989. 1990. 1991. 1992; Tanaka et
al.. 1989: Bello and Rey. 1990: Roberts and Tattersall. 1990:
Islam et al.. 1993: Jenkins et al.. 1993: Persons et al.. 1993:
Thompson et al.. 1994). The cytogenetic data have allowed
investigators to evaluate the role of some of these
chromosomal alterations using more sensitive and precise
methods. that is using highly polymorphic markers for lin-
kage analysis of familial cancer and loss of heterozygosity
studies in sporadic tumours.
Linkage
The majority of ovarian cancers are sporadic. but a predis-
position to tumour development can be inherited as an
autosomal dominant trait. Female members of ovarian
cancer families may have a lifetime risk for ovarian cancer 2-
or 3-fold greater than the general female population. and are
often found clustered with stomach. breast and colon cancer
(Blackett and Sharp. 1994). Recently. a large international
consortium has used polymorphic DNA markers to link
more than 200 families with breast and ovarian cancer to a
susceptibility gene at chromosome 17q21. known as BRCA1.
leading to the recent identification of the BRCA1 gene (Miki
et al.. 1994). The combined data have demonstrated that in
almost all families with breast and ovarian cancer. and about
half of those with only breast cancer. the disease can be
linked to the BRCA1 gene (Black and Solomon. 1993). Loss
of heterozygosity studies on tumours from patients within
ovarian cancer families have also consistently shown
chromosome 17 loss within the region which contains the
wild-type BRCA1 gene (Smith et al.. 1992). leaving the
mutant BRCA1 gene on the remaining chromosome 17. sug-
gesting that it is a tumour-suppressor gene. Overall. germline
BRCA 1 mutations may account for as many as 10% of
ovarian cancers (Blackett and Sharp. 1994). however high
loss of heterozygosity in the BRCA1 region of 60% in
sporadic ovanran tumours suggests that somatic alterations in
BRCA1 (not observed by Futreal et al.. 1994) or a nearby
gene may be important in a larger proportion of these
cancers.
Table I Ov-erall loss of heterozvigositv in ovarian cancer
Chromosome arm .411ele loss 0
17p 380 612 (62)
17q 370 655 (56)
22q 53 114 (46)
18q 60 142 (42)
6q 111 280 (40)
13q 105 260 (40)
Xp 30 78 (38)
Sq 41 114 (36)
6p 60 171 (35)
19p 39 113 (35)
lIp 130 398 (33)
9p 49 157 (31)
Data summan'sed from Eccles et al. (1990. 1992b.c). Lee et al.
(1990). Okamoto et al. (1991). Sato et al. (1991). Tsao et al. (1993).
Viel et al. (1991. 1992). Zheng et al. (1991. 1993). CheneVix-Trench et
al. (1992. 1994). Gallion et al. (1992). Jacobs et al. (1992. 1993).
Jones and Nakamura (1992). Saito et al. (1992. 1993). Vandamme et
al. (1992). Dodson et al. (1993). Foulkes et al. (1993a-c).
Kiechle-Schwarz et al. (1993). Kupryjanczvk et al. (1993). Learv et
al. (1993). LownY and Atkinson (1993). Phillips et al. (1993).
Tavassoli et al. (1993). Yang-Feng et al. (1993). Allan et al. (1994).
Englefield et al. (1994). Frank et al. (1994). Futreal et al. (1994). Kim
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Figure 1 Frequency of allele loss on each chromosome arm. The
horizontal line (33%) represents the average LOH (taken as total
number of chromosome arms lost total number of tumours). The
location of some known candidate genes is indicated.
Loss of heterozygositv
The search for loss of heterozygosity is now widely accepted
as a means of identifying recessive genes involved in the
aetiology of hereditary and sporadic tumours. Frequent allele
loss at specific loci suggests that these loci may contain
tumour-suppressor genes. Some authors (Cliby et al., 1993)
have suggested that loss of heterozygosity occurring more
frequently than a baseline level of 35% is more likely to
represent important. potentially causative, genetic events than
a secondary phenomenon associated with generalised
genomic instability. Some loss of heterozygosity studies have
shown quite variable results, making it often difficult to
identify clearly regions of interest. These differences may be
due to insufficient numbers of tumours being tested, uninfor-
mative loci on the particular chromosome arm being tested
or the inability of the researcher to dissect tumour material
away from normal tissue. Other causes may be more
significant. such as inherent genetic differences in the study
population or differences in the tumour subtype. stage. grade
or incidence of prior treatment in the tumour being
evaluated. In an attempt to adjust for some of these
variables. results of chromosome arm loss from a number of
loss of heterozygosity studies have been pooled (Table I and
Figure 1). An attempt has been made to avoid duplicating
data from different studies and, where possible. only results
from malignant tumours have been included. This approach
may not be totally valid, as it would not expose all potential
tumour-suppressor genes mutated in more subtle ways. such
as by small deletions or point mutations, however it does
provided a useful indicator of generalised allele loss. This is
especially significant in ovarian cancer. in which loss of
heterozygosity for a single marker may frequently equate
with loss of heterozygosity of all informative markers on a
chromosome arm (Foulkes et al.. 1993a). Similar regions of
allele losses are seen in a variety of solid tumours. for
example 17p is lost not only in ovarian cancer (63%). but
also in osteosarcoma (71%). non-small-cell lung cancer
(62%). oesophageal (62%). breast (61%) and hepatocellular
(54%) cancer (Yamaguchi et al.. 1992; Tsuchiya et al.. 1992:
Aoki et al.. 1994; Devilee et al.. 1991: Fujimori et al.. 1991)
respectively. Several chromosomal regions identified as con-
taining potential tumour-suppressor genes implicated in
ovarian cancer are discussed in detail below.
Chromosome 6
Allelic losses of up to 50% involving 6q have been frequently
reported (38%. Table I). Several studies have shown byGenetc arnysis of ovan cancer
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either loss of heterozygosity (Sato et al.. 1991 Saito et al..
1993) or cytogenetic abnormalities (Wake et al., 1980). that
these changes occur more frequently in serous adenocar-
cinomas, implying that 6q may be important in the
pathogenesis of the more common serous adenocarcinomas
(Sato et al.. 1991). Evidence for a critical region on
chromosome 6 (6q26-6q27) has been provided by allele loss
studies using cosmids derived from chromosome 6 (Saito et
al., 1992) on a panel of ovarian tumours. Two cosmids
delineated the region of minimal loss in the tumour from one
patient to chromosome 6q27. The potential distance between
the two cosmids has been estimated to be 2 megabases based
on the CEPH genetic map (Saito et al., 1992). Using cosmids
mapped to chromosome 6q by Nakamura and co-workers
(Saito et al.. 1992), six cell lines have been studied in detail
using fluorescence in situ hybridisation (Lastowska et al..
1994). Three of the six cell lines show abnormalities in this
region, which suggests that a gene (or genes) localised to
6q26-27, and also a region proximal to 6q24. may play a
role in the development of ovarian cancer. Recently, Wan et
al. (1994) have identified three regions on chromosome 6
which show increased levels of allele loss: at 6q27, at a more
proximal site (6q21-25) and at a region on the short arm
that includes the WAF-1/Cip-l gene (6p21).
Chromosome transfection studies have shown that
chromosome 6. and especially 6q, contains gene(s) that cause
senescence (Hubbard-Smith et al., 1992; Gualandi et al..
1994; Sandhu et al.. 1994) and/or reverse the tumorigenic or
metastatic features of various tumour cell lines (Trent et al..
1990; Yamada et al., 1990; Negrini et al., 1994; Welch et al..
1994). It remains to be seen whether these regions contain a
gene or genes involved in ovarian cancer.
Chromosome 11
In epithelial ovarian cancer, loss of heterozygosity of 33% on
lIp has been reported (Table I). This may be a late event in
tumour progression (Vandamme et al., 1992). The important
sites of deletion have been mapped to llpl3 between loci
Dl1S16 and catalase, corresponding to the position of the
Wilms tumour gene (W71), although no abnormalities in the
WT1 gene have been found (Viel et al., 1994), and to
llpl5.5, telomeric to the P-globin gene (Vandamme et al.,
1992; Viel et al., 1992). In some tumours there was con-
comitant deletion in both regions, suggesting that they may
act synergistically. Recently, it has been shown that introduc-
tion of normal human chromosome 11 altered the trans-
formed phenotype of an ovarian cell line (Cao et al.. 1993).
Foulkes et al. (1993b) analysed 11 q in response to the
numerous cytogenetic abnormalities including translocations
and deletions involving 1 lql3-qter in epithelial ovarian
cancer. They found a minimal region of loss at 1 Iq23.3-qter.
thus suggesting that there may be a third tumour-suppressor
gene on chromosome 11.
Chromosome 13
The overall loss of heterozygosity of chromosome 13q alleles
is 41% (Table I). Initially the retinoblastoma (RB) gene locus
(Cliby et al., 1993) was a candidate tumour-suppressor gene
for ovarian cancer, however inactivation of the RB gene
leading to abnormal RB protein expression is extremely rare
(Dodson et al., 1994; Liu et al.. 1994). This would suggest
that another tumour-suppressor gene(s) other than RB must
be involved on chromosome 13 in the progression of ovarian
cancer. Recently, a gene predisposing for familial breast
cancer, BRCA2. has been mapped to 13ql2-13 (Wooster et
al.. 1994). Loss of chromosome 13 appears to be specific for
high-grade tumours (Kim et al.. 1994). which suggests that
allelic loss of 13 either causes or occurs soon after the
development of invasive or metastatic abilities.
Chromosome 17
Allele loss occurs frequently on chromosome 17 (17p. 62%;
17q, 56%; Table I). These figures may be partly explained by
the p53 gene, as discussed below.
p53 Mutations in the p53 tumour-suppressor gene. which is
located on 17p, occur in up to 50% of all human cancers.
and are found in both inherited and sporadic tumours. Two
biochemical features are clearly important in the normal role
of p53 for growth suppression. First, p53 binds to and
thereby suppresses various transcription factors, including
those that bind to TATA elements and, second, it transcrip-
tionally activates the expression of a number of genes which
encode proteins that can suppress cell division. Tumour data
have shown two types of mutational events in p53 are
required to cause a phenotypic effect on cell growth. First,
the loss of the wild-type allele, which is frequently observed
when high loss of heterozygosity is seen on chromosome 17p
(p53 is located on 17pl3.l). Second, many studies have
shown a high frequency of mutations in p53 (546/1125; 49%)
(Table II). Point mutations within the p53 gene frequently
Table II p53 mutations in ovarian cancer
Histologi
Method Benign Borderline Mfalignant Reference
Chemical mismatch 11 20 Sheridan et al. (1993)
SSCP 016 11 30 Mazars et al. (1991)
SSCP 9 31 Okamoto et al. (1991)
SSCP 0 2 10 14 Kihana et al. (1992)
SSCP 0 6 5 10 Naito et al. (1992)
SSCP 34 66 Milner et al. (1993)
IHC 0 13 54 107 Marks et al. (1991)
IHC 0 3 0 1 11 16 Eccles et al. (1992a)
IHC 0 2 10 14 Kihana et al. (1992)
IHC 5498 Bosari et al. (1993)
IHC 15 52 Kohler et al. (1993a)
IHC 26 38 Kupryjanczyk et al. (1993)
IHC 0 17 2 49 Berchuck et al. (1994)
IHC 16 33 Frank et alt (1994)
IHC 147 284 Hartmann et al. (1994)
IHC 0 14 2 7 24 55 Henriksen et al. (1994)
IHC 0 6 0 10 24 45 Klemi et al. (1994)
IHC 0 47 0 16 49 147 Imai et al. (1994)
IHC 8 15 Liu et al. (1994)
IHC 28 50 Renninson et al. (1994)
Total 0 122 2 86 546 1125
0h0 2% 49%
aStudy contained only stage I and II tumours. IHC. immunohistochemistry: SSCP. single-strand conformation polymorphism.
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cause conformational changes w-hich stabilhse and extend the
half-life of the mutant p53 proteins. causina them to
accumulate in the nucleus and allowxing them to be detected
immunohistochemicallx. ser-ing as a rapid and effectix-e
means of screening for p53 mutations. Clearl. p53 mutation
is not a common feature of benign (O 122 tumours) or
borderline tumours (2 866 2'0( (Table II>. Furthermore. p53
mutations appear to be less common in localised tumours.
occurring in 105 284 (3-'~o stage I and II tumours as com-
pared w-ith 351 608 (580o( late-stage tumours (stages III and
IV) (Table III). This would suggest that pS3 mutations occur
as a later ex-ent in tumour progression. Although p53 ox-erex-
pression occurs more frequentlx- in late-stage tumours.
oN-erexpression has not been showxn to has-e a correlation
w-ith surx-ixal (Hartmann et al.. 1994).
As in other tumours. the analysis of the spectrum of
mutations in the p53 gene may prox-ide information about
the origins of the mutations that gix-e rise to the tumours.
Prex-ious studies (Hollstein et al.. 1991 hax-e shown that 98°o
of mutations fall in exons 5-. w-hich are highlx- ex-olu-
tionanlx conserx-ed. In the analysis of ox-an'an cancer (Kohler
et al.. 1993b( a predominance of transitional mutations
(o20. as xwell as transx-ersions (240 o) and microdeletions
(40(o has been obser-ed. GC-*AT transitional mutations
occur at CpG dinucleotides and are assumed to result from
the spontaneous deamination of 5-methylcytosine because of
spontaneous errors in DNA synthesis and repair. rather than
direct interaction w-ith carcinogens. Increased mutation rates.
perhaps caused by errors in DNA replication and repair
follow-ing o-ulation. is a fax-ourable molecular mechanism to
explain Fathalla's hxpothesis (Fathalla. 19-1 . especially
since no enx-ironmental carcinogens hax-e been conx-incinglI-
associated w-ith ox-arian cancer.
Other chromosome 1- tiumrour-suppressor genes Allelic loss
on lVq may rel- on the loss of txwo or more genes. The
familial ox-arian breast cancer locus (BRCA4 1 ) on
chromosome IVq2l is a likely candidate. howex-er. it does not
appear to be important in sporadic cancer (Futreal et al..
1994(. Sex-eral inx-estiaators hax-e found loss at more distal
Iq regions to the BRC.41 gene (Eccles et al.. 1990: Russell
et al.. 1990: Foulkes et al.. 1991: Yang-Feng et al.. 1993 . It
appears that 1 7q loss occurs before 1 I7p loss. as loss of
heteroz-xgosity at 1 q has been reported in benign and
borderline oxarian tumours (Russell et al.. 1990: Gallion er
al.. 1992). MlanN- studies hax-e shoxwn that a great majority of
ox-arian tumours hax-e probably lost one copx of an entire
chromosome 1-. thus deleting p53. BRC.1I and other poten-
tial tumour-suppressor genes in a single ex-ent. In most cases.
the loss appears to in-olx-e the w-hole chromosome. probably
due to non-d-sjunction. xwith or wxithout reduplication
(Foulkes et al.. 1993a(.
Chromosome 1J?
The DCC locus (deleted in colon cancer) on chromosome 18
appeared to be a good candidate gene for ox-arian cancer.
particularly as both colon and oxarian carcinomas arise from
normal epithelia. xwhich suggests that similar genetic events
may be required. Overall. 420o of tumours show-ed loss of
heterozygositv on 18q (Table I). w-hereas 18p only show-ed
140o loss. The DCC locus and alleles surrounding it have
been analvsed in detail (Chenevix-Trench et al.. 199r2. High
loss of heteroz-zosity wvas found at one or more loci in
approximately 60°o of the tumours studied. and tended to
occur more frequently in advanced staze tumours. The
smallest region of overlap of allele loss unexpectedly did not
include the DCC locus. This suggests that another locus
exists on 18q near the DCC gene.
Chromosome X'
As oxvarian cancer is a female cancer. there might be a
specific role for the X chromosome. Ox-erall. both Xp (380o)
and Xq (2900o have a high lexel of loss of heterozxvositV
(Table I>. This appears to be highest around the OTC locus
(Xp1l.l) (530o: 9 17) (Yang-Feng ei al.. 1992. 1993). Loss of
heterozxgosity on Xp may- be specific for ovarian cancer
(Yani-Feng et al.. 1993). howxexer other tumours have not
yet been tested with X and chromosome markers.
Cvtozenetic analysis of the X chromosome in oxarian
patients frequently identifies the loss of the X chromosome
often at quite high lexels. for example Tanaka et al. (1989(
found loss of in 8 9 oxarian carcinomas. It has been
suggested that loss of X may be a primary or early ev-ent in
ovarian tumour dexelopment (Thompson et al.. 1994(. In
addition to allele loss. the selectixe inactix-ation of X
chromosome genes by hypermethylation may contribute to
the inactivation of a tumour-suppressor gene. how-ever this
form of allele inactixation is thought to be a secondarx exent
in tumour progression (Laird and Jaenisch. 1994.
Conclusion
The positional cloning of putatix-e tumour-suppressor genes
identified from allele loss studies *-ill lay the foundation for a
better understanding of the pathogenesis of ox-arian cancer.
The identification of BRC41 and BRC.4' u-ould be of direct
clinical benefit to probands in breast- oarian cancer
families. The isolation and characterisation of oncogenes and
tumour-suppressor genes has sexveral clinical applications.
First. persons at high risk of oxarian cancer (such as oxarian
cancer families ) can be screened by molecular approaches
and offered prophylactic oophorectomy if they carry the
defectixe gene. Second. it is also conceixable that such genes
or their products may be the basis of a general screening
approach for ox-arian cancer. Diaanosis could be made
relatixely simply by the identification of mutant gene prod-
ucts in the blood. or by the detection of antibodies made by
the patient against the mutant gene product. Third. neu-er
therapeutic approaches designed to inactix ate mutant gene
products (e.g. c-erbB-2' or mimic or restore the normal
biological function of genes like p53 will be possible. Finally.
gene therapy x-ould be an appealingz xvay to restore function
in patients x-ho hax-e oxarian cancer once it is possible to
Table III \uta::on ::r oxvaran cancer b! Sace
Stt-' I anci II 5raze-t III and II- R1t-re7 L &
V 46 Ay 92 \tark; tt s a. 1991
M1azar; t-l a! 1991
Bosarn i a!. X1993
' "2 Kohler et al. a 1993a
6 22 ' 4'2 Milner atal. 1993)
Th~56 14- 2> Hartmann eia. a 1994
26 'V I 29 Hennrksen etcl. a 19941
6, In 18 >> Kilemi et al (1994)
NO K 6 Imai it a!. 19944
H-4 >sb46 Renninson tat . 11994
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surmount the technical challenges of delivering the gene to
the appropriate tissue. Genetic analysis of common cancers
can thus lay the foundation for more appropriate manage-
ment and cure for the majority of the patients in the
future.
Note added in proof
Approximately 10% of sporadic ovarian cancers have recently been
shown to contain mutations in BRCA1 (Hosking et al.. 1995: Mera-
jver et al.. 1995).
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